NCT04815213View on ClinicalTrials.gov

The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2027

Conditions
Premature Ovarian Failure
Interventions
BIOLOGICAL

expanded autologous bone marrow derived MSC Intravaginally

Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary

BIOLOGICAL

expanded autologous bone marrow derived MSC Laporoscopic

Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary

BIOLOGICAL

EV

Extracellular vesicles injection

Trial Locations (1)

Unknown

Cell Therapy Center, University of Jordan, Amman

All Listed Sponsors
lead

University of Jordan

OTHER

NCT04815213 - The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans | Biotech Hunter | Biotech Hunter